Evidence map›Paper›PMID 41993253›Full record

ArticlebioRxiv : the preprint server for biology2026

Enteroviral epitope mimicry enables NK cell-mediated targeting of ASPH in hepatocellular carcinoma.

Man Hsin Hung, Qin Li, Limin Wang, Marshonna Forgues, Andrew S Lee, Lisa M Jenkins, Tapan K Maity, Jesse Buffington, Jittiporn Chaisaingmongkol, Siritida Rabibhadana and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Man Hsin HungLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.ORCID 0000-0002-7449-5857
Qin LiLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.
Limin WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.
Marshonna ForguesLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.
Andrew S LeeLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.ORCID 0009-0000-4441-8028
Lisa M JenkinsMass Spectrometry Resource, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.
Tapan K MaityMass Spectrometry Resource, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.
Jesse BuffingtonAntibody Engineering Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.
Jittiporn ChaisaingmongkolLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, Thailand.
Siritida RabibhadanaLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, Thailand.
Mathuros RuchirawatLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok, Thailand.
Mitchell HoAntibody Engineering Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.ORCID 0000-0002-9152-5405
Xin Wei WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892.ORCID 0000-0001-9735-606X

Funding

Development of new antibody-based cancer therapiesZIABC010891 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HO, MITCHELL · 2009 to 2025
$21.4M
Strategies for improving early detection, diagnosis and treatment of liver cancerZIABC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$18.1M
The role of cancer stem cells in liver cancer heterogeneity and subtypesZIABC010876 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$12.6M
Liver Cancer ProgramZIABC011870 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2019 to 2025
$10.1M
The identification of human hepatocellular carcinoma metastasis genesZIABC010877 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$8.3M
Antibody Engineering ProgramZICBC011891 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HO, MITCHELL · 2019 to 2025
$4.5M
Intramural NIH HHS ZIA BC010313Intramural NIH HHS ZIA BC010876Intramural NIH HHS ZIA BC010877Intramural NIH HHS ZIA BC010891Intramural NIH HHS ZIA BC011870Intramural NIH HHS ZIC BC011891
6 · The paper itself

Abstract

Cancer development is shaped by host-microbe interactions, including viral infections. While several viruses are established oncogenic drivers, their potential protective roles in cancer remain unclear. Here we identify a dominant antibody response to CE1, a consensus epitope of enterovirus and rhinovirus, that is associated with reduced hepatocellular carcinoma (HCC) incidence and mortality. Anti-CE1 antibodies selectively recognize HCC cells and mediate anti-tumor activity through NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Mechanistically, anti-CE1 antibodies cross-react with aspartate β-hydroxylase (ASPH), with CE1-ASPH sequence homology underpinning tumor recognition and cytotoxicity. Clinically, ASPH is aberrantly upregulated in HCC and correlates with inferred NK cell-associated ADCC activity and improved survival in CE1-seropositive patients. Collectively, these findings reveal a mechanism by which antiviral humoral immunity confers cancer protection through molecular mimicry and highlight anti-CE1 immunity as a potential therapeutic strategy in HCC.

Identifiers

PMID41993253
PMCPMC13082011

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.